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Introduction
Figures 1 and 2) [14] . Motility investigations were performed off enterokinetic or Full thickness gastrointestinal biopsies (FTB) 145 FTB when available from previous intra-operative specimens were reported by 146 specialist histopathologists with an interest in GINMD. Abnormalities described on 147 these expert reports were noted and classified retrospectively by investigators 
Glucose-Hydrogen-Methane Breath Tests 152
Glucose-hydrogen-methane breath tests were used to diagnose small intestinal 153 bacterial overgrowth (SIBO). Patients ingested 50 g dextrose monohydrate (glucose) 154 made up to 250 ml with water. End-expiratory breath samples were taken at baseline 155 for hydrogen (H 2 ) and methane (CH 4 ) levels and samples were obtained every 15 156 minutes for 2 hours after ingestion of the test drink and analysed using a Quintron Long-term Parenteral Nutrition protocol 164 The majority of patients were managed with single-lumen tunnelled central venous 165 catheters and PN was delivered using a stringent catheter care protocol either by the 166 patients, their relatives or trained nursing staff, as previously described [23] . Patients 167 were given the minimum number of nights PN to meet their nutritional needs and 168 encouraged to have oral and/or enteral nutrition if able. Where possible, parenteral 169 lipids were delivered once or twice per week and lipid dosing was limited to 1 170 g/kg/day. All patients were reviewed regularly in the clinic and the PN content and 171 volume optimised according to on-going requirements. for the purposes of this study. In addition, 5 patients did not require PN after 227 completing an IFU assessment, and were also excluded from further analysis.
Of the remaining 52 patients referred to the IFU with an initial working diagnosis of 231 primary GID, 7/52 (13%) did not meet diagnostic inclusion criteria for this study 232 (CIPO or pragmatic GID criteria; Figure 1 ) [10, 14] , and were also excluded. Of these 233 7 excluded patients, noneafter evaluation on the IFU -had evidence of small 234 bowel involvement, none had GINMD (2/7 had FTBs from surgical specimens that 235 were normal, 5/7 were opiate dependent, 4/7 were ultimately diagnosed with other 243 All patients included in this study (n=45) met the pragmatic GID diagnostic criteria (Table 2) . 
Characteristics of patients with primary Gastrointestinal dysmotility (GID)

296
Whilst not statistically significant, there were trends towards higher prevalence of 297 visceral myopathy on abnormal FTBs in CIPO (9/11 (82%) vs. non-CIPO 2/6 (33%), 298 Fishers exact test P=0.11) and higher prevalence of enteric neuropathy in non-CIPO 299 patients (CIPO 2/11 (18%) vs. non-CIPO 4/6 (67%), Fishers exact test P=0.11). 
